Document:

Exhibit 10.47

 

Certain identified information has been excluded from the exhibit
pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***]

 

CONSULTING AGREEMENT

 

THIS AGREEMENT is dated as of April 1,
2022 (the “Effective Date”)

 

BETWEEN:

 

ProMIS Neurosciences Inc., a
corporation existing under the federal laws of Canada with a registered address at 1920 Yonge St., Suite 200, Toronto, Ontario, M4S 3E2
(the “Company”)

 

AND:

 

Larry Altstiel, M. D., PhD (the
 “Consultant”), with an address at [***]

 

WHEREAS:

 

		A.	The Company wishes to engage the Consultant as its duly appointed Chief Medical Officer to support the
Company’s development and scientific programs, including developing strong scientific rationale for investors or potential partners;

 

		B.	The Consultant also provides consultant services to a third party, Pinteon Therapeutics, related to the
creation of full length antibody therapies for tau proteins (the “Excluded Subject Matter”); and

 

		C.	The nature of the Consultant’s work contemplated under this Agreement does not relate to the Excluded
Subject Matter;

 

IN CONSIDERATION OF the mutual covenants
and agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby mutually acknowledged,
the parties agree as follows:

 

PROVISION OF SERVICES

 

	1.	Services. Commencing on April 1, 2022 (the “Start Date”), the Consultant will
[was] appointed as Chief Medical Officer, an officer of the Company, and will perform for the Company (as an independent contractor and
not as employee, agent, partner or joint venturer) the services described in Schedule A (collectively, the “Services”).
Schedule A forms an integral part of this Agreement and is hereby incorporated by reference. Consultant will perform the Services for
a maximum of twenty- five (25) hours per week unless the Parties agree to a different time commitment over an agreed period of time.

 

	2.	Quality of Service. The Consultant represents, warrants, and covenants that he will (and will cause
the Consultant Representatives to: a) perform the Services in a timely, competent and professional manner in accordance with the standards
and practices commonly expected of qualified and experienced providers of similar services, (b) perform the Services in compliance with
all applicable laws, rules, ordinances and regulations that are now applicable to the Consultant, the Consultant Representatives or the
Services, whether federal, state, provincial, municipal or otherwise, and (c) at all times act in the best interests of the Company and
perform the Services in a faithful manner to the best ability of the Consultant and each of the Consultant Representatives. The Consultant
may provide services to other clients during the Term of this Agreement, provided that the activities do not interfere with or conflict
with the Consultant’s obligations to the Company under this Agreement and provided that the Consultant obtains the consent of the
Company prior to entering into any new engagements, such consent not to be unreasonably withheld.

 

     

     

    

 

	3.	Subcontracting and Assignment. The Consultant will not, without the prior written consent of the
Company (which consent the Company may in its sole discretion withhold), subcontract, delegate or otherwise assign any or all of the Consultant’s
obligations under this Agreement.

 

TERM AND TERMINATION

 

	4.	Term. This Agreement shall commence on the Start Date and will continue on until April 1, 2023
(the “Term”), unless terminated earlier in accordance with this Agreement. This Agreement may be renewed for a subsequent
period or periods of twelve months or more, upon mutual consent of both parties. This Agreement may be terminated as described in Schedule
A.

 

	5.	Effect of Termination. If this Agreement is terminated as provided herein, the Company’s
sole liability for Consultant’s Services shall be to pay the Consultant for all properly performed Services to the effective date
of termination. The rights and responsibilities of the Parties under Paragraphs 1, 5-10, and 12-15 survive the termination or expiration
of this Agreement.

 

	6.	FEES AND EXPENSES

 

Fees and Expenses.

 

		a)	In consideration for performing the Services, the Company will pay the Consultant a monthly fee of US$19,000
(nineteen thousand US dollars). Each such monthly payment shall be made on or before the first business day of the succeeding month. The
Company will reimburse the Consultant in accordance with its normal policies and practices for the Consultant’s reasonable, out-of-pocket
expenses or disbursements actually and necessarily incurred or made by the Consultant in connection with the performance of the Services
(collectively, “Expenses”). All Expenses will be reimbursed within five business days of submission of receipts and
expense reimbursement request. Any individual expense exceeding US$500 (five hundred US dollars) requires advance written approval from
ProMIS Neurosciences. During the contract term, it is understood that the Consultant shall be available for the requirements of ProMIS
to achieve the objectives set out in Appendix A. During the contract term, it is also understood that the Consultant will devote, on average
over any calendar month, 50% of his time to achieve the Objectives set forth in Appendix A.

 

    2

     

    

 

		b)	On or before the Effective Date of this Agreement, the Company will provide the Consultant a copy of the
ProMIS Neurosciences Inc. Stock Option Plan approved the Board of Directors (the “Option Plan”) and all other documents
setting forth the terms and conditions applicable to options in the Company. Within 30 days of the Effective Date of this Agreement, ProMIS
will award 1.85MM stock options to the Consultant, on standard terms and conditions governing such options applicable to other option
holders under the Option Plan, subject to final approval by the Board of Directors. The Company will grant the options at a strike price
equal to the volume weighted average share price of the preceding 5 trading days and shall have a 10-year exercise period from the date
the options have been granted to the Consultant. The share options will vest in equal monthly portions over 48 months. In case of “Change
of Control” or other “Triggering Event” as those terms are defined in the Option Plan, all options, whether
vested or not, will immediately vest. Upon termination of this Agreement by the Company without cause, all vested options will be vested
and be exercisable in accordance with the Option Plan.

 

Any Option Commitment (as defined in the
ProMIS Neurosciences Inc. Stock Option Plan) or stock option agreement between the parties shall include the terms set out in this paragraph
3.0(b) of the Option Plan. ProMIS hereby represents and warrants that all necessary corporate action has been taken by or on behalf of
ProMIS to grant the Options in accordance with this paragraph 3.0(b) of the Option Plan.

 

	7.	Taxes and Benefits. The Consultant represents, warrants and covenants that the Consultant is acting
and will act only as independent contractor (and, in any event, never as an employee of the Company). The Consultant acknowledges and
agrees that, in its performance under this Agreement, neither the Consultant nor either Consultant Representative, will be entitled to
any employee-like benefits or any direct or indirect compensation other than that expressly set out in this Agreement. The Consultant
will, as an independent contractor, collect and/or remit as required, all amounts, and will register with any workers’ compensation
entities or other governmental bodies, and deal with all tax and other requirements, and satisfy all applicable compliance requirements,
as required or permitted under law by all municipal, provincial, state or federal governments. The Consultant agrees that the Company
will not be responsible for registering under any workers’ compensation legislation or for withholding or remitting any amounts
for income taxes, social security taxes, (un)employment insurance, or other deductions that would be required in an employment relationship
in any jurisdiction.

 

	8.	Insurance. The Company will maintain insurance coverage in accordance with normal Company business
practices, including Directors & Officers Liability Insurance, Professional Liability Insurance and General Liability Insurance. As
the Consultant will be serving as Chief Medical Officer, an appointed officer of the Company, it is the Company’s intent that the
Consultant will be entitled to coverage under such insurance policies to the same extent as all other officers of the Company.

 

    3

     

    

 

CONFIDENTIALITY AND RESTRICTIVE COVENANTS

 

	9.	Definitions. In this Agreement,

 

(a)               “Company
Entities” means the Company and its subsidiary, parent and affiliate corporations identified on Schedule B attached to this
Agreement (the “Company Entities”), to the extent that such reference does not require any subsidiary party to be added as
a party to this Agreement other than as a third party beneficiary, each of whom will be expressly deemed an intended third party beneficiary
of this Agreement and will have the right to enforce the terms and conditions of this Agreement; and

 

(b)              
“Confidential Information” means all information in any form (including all electronic, magnetic, physical,
intangible, visual and oral forms) and whether or not such information has been marked or indicated as confidential, that is known, held,
used or disclosed by or on behalf of the Company Entities in connection with its business, and that, at the time of its disclosure: (i)
is not available or known to the general public; (ii) by its nature or the nature of its disclosure, would reasonably be determined to
be confidential; or (iii) is marked or indicated as proprietary or confidential; and includes patent applications, trade secrets, technology,
know-how, technical information, supplier and customer information (whether past, present, future and prospective), strategic plans, financial
information, marketing information, information as to business opportunities, strategies and research and development, consultation records
and plans, communications, meetings, conversations, surveys, third party data and studies

 

	10.	Confidentiality. In connection with the Consultant’s performance under this Agreement, the
Company has furnished or may furnish to the Consultant, or the Consultant may acquire, develop or conceive of, Confidential Information,
all of which the Consultant will treat strictly in accordance with this Agreement. For greater clarity, the parties hereby acknowledge
and agree that Confidential Information can encompass information regardless of whether it was disclosed prior to the date of this Agreement
or after. In connection with this,

 

(a)              
Obligations—at all times during and after this Agreement (subject to §10(b)), the Consultant will protect
the Confidential Information using a reasonable degree of care, and will take all reasonable steps to safeguard the Confidential Information
from unauthorized disclosure, and without limiting the foregoing will not, directly or indirectly, (i) copy or reproduce any of the Confidential
Information, (ii) use any Confidential Information for any purpose other than the proper performance of the Consultant’s duties,
or (iii) subject to §10(c), disclose any of the Confidential Information except strictly to those of the Company or Company Entities’
directors, officers, consultants, attorneys, accountants, advisors and personnel to whom disclosure is necessary to carry out the Consultant’s
duties, or as otherwise directed or authorized by the Company.

 

(b)               Exceptions—this
 §10 imposes no obligation upon any person with respect to any information or part thereof that the Consultant can establish that,
other than as a result of a breach of this Agreement, (i) was in the Consultant’s possession prior to entering into this Agreement
without any restriction of confidentiality owed to any Company Entity, (ii) is or becomes generally available to the public rightfully
without restrictions of confidentiality, or (iii) becomes available to the Consultant after the term of this Agreement from a third party
(other than any Company Entity) who has no obligation of confidentiality with respect thereto,

 

    4

     

    

 

(c)               Required
Disclosures—if the Consultant is requested or required (including, without restriction, by oral questions, interrogatories,
requests for information or documents, subpoena, civil investigative demand or other similar process) by any law to disclose any Confidential
Information, he may disclose strictly that Confidential Information for which disclosure is required to comply with any such applicable
law, provided that the Consultant (i) unless prohibited by such applicable law, provides the Company with written notice as soon as practicable
in the circumstances so that the Company may contest the disclosure or seek an appropriate protective order, and (ii) cooperates reasonably
and in good faith with the Company in its efforts to prevent, restrict or contest such required or requested disclosure.

 

(d)              
Acknowledgement—the Consultant acknowledges and agrees that the right to maintain the confidentiality of Confidential
Information, and the right to preserve the Company’s goodwill therein, constitute proprietary rights which the Company is entitled
to protect.

 

	11.	Intellectual Property. In this Agreement, “Intellectual Property” means any
and all inventions, original works of authorship, developments, concepts, improvements, designs, social media posts, logos, discoveries,
ideas, work product, data, and all tangible and intangible materials, in each case whether or not patentable or registrable under copyright
or other intellectual property laws anywhere in the world that are developed, created, or otherwise brought into existence by the Consultant,
but for certainty excludes any and all inventions, original works of authorship, developments, concepts, improvements, designs,
social media posts, logos, discoveries, ideas, work product, data, and all tangible and intangible materials related to the Excluded
Subject Matter that are developed, created, or otherwise brought into existence by the Consultant. The Consultant hereby acknowledges
and confirms that any and all Intellectual Property arising from the consulting services and activities of the Consultant to the Company
shall be the exclusive property of the Company. The Consultant hereby assigns, transfers, and sets over, and for greater certainly agrees
to promptly assign transfer, and set over, to the Company all of his rights, title, and interest in, to, and associated with the Intellectual
Property. The Consultant hereby waives, and agrees to waive, all of his moral rights in and to the Intellectual Property in favour of
the Company. Upon the reasonable request of the Company, the Consultant will execute all necessary papers to confirm the Intellectual
Property assignments contemplated herein. For certainty, the Company agrees that the Consultant may continue to work with Pinteon Therapeutics
on the Excluded Subject Matter, and any such intellectual property created in relation to the Consultant’s work with Pinteon Therapeutics
on this Excluded Subject Matter will not be captured by this provision. The Consultant and the Company agree that the Consultant will
not be involved in any of the Company’s activities relating to the Excluded Subject Matter.

 

	12.	No Liability. The Consultant shall indemnify and hold harmless the Company from any claim or demand
made by (a) any governmental authority with respect to the fees paid hereunder, or (b) any person with respect to the Services provided
pursuant to this Agreement, except to the extent that the Company has explicitly assumed liability pursuant to this Agreement. The Company
shall indemnify and hold harmless the Consultant against any and all claims, complaints, actions, proceedings, lawsuits, and judgments
arising from any action or inaction of the Consultant while carrying out the Services, except those which arise from fraud or other criminal
acts by the consultant. This indemnity provision will survive the Termination of this Agreement. Nothing in this paragraph of the Agreement
shall alter, impair, waive or otherwise affect the Company’s responsibilities under paragraphs 5, 6, or 12.

 

    5

     

    

 

	13.	Severability. If any provision of this Agreement is held invalid, illegal or unenforceable, the
remaining provisions will not be affected.

 

	14.	Governing Law, Breach, and Dispute Resolution. This Agreement will be governed by and interpreted
in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein without reference to its conflict of
laws principles. If one Party commits a material breach of one or more terms of this Agreement which cannot or is not cured, the other
Party shall recover its reasonable attorneys’ fees and costs incurred in connection with such breach and enforcement of its rights
under this Agreement. The Parties will attempt to resolve any dispute under this Agreement, including any issues of arbitrability, interpretation,
validity or enforcement of the Agreement, through mediation under the Canadian Dispute Resolution Procedures of the International Centre
for Dispute Resolution Canada (ICDR). If the Parties are unable to resolve the dispute through mediation, the dispute will be resolved
through arbitration before a single arbitrator pursuant to the Canadian Dispute Resolution Procedures of the ICDR. The arbitrator shall
have no authority to modify the rights and obligations of the Parties under this Agreement. The decision of the arbitrator shall be final
and binding on the Parties. Any mediation or arbitration shall take place in the city of Toronto, Ontario, Canada. Any judicial proceedings
to vacate or confirm any arbitration award shall be heard by a court with jurisdiction over the matter located in the city of Toronto.
As used in this paragraph, the term “Parties” includes the Company Entities.

 

	15.	Notice. Every notice, request, demand or direction (each, for the purposes of this section, a “notice”)
to be given pursuant to this Agreement by either party to another will be in writing and will be delivered or sent by registered or certified
mail postage prepaid and mailed in any government post office or by email, or other similar form of written communication, in each case,
addressed as above or to another address as notified hereunder from time to time.

 

	16.	Interpretation. In this Agreement, (a) “§” means a section, subsection,
paragraph or sub-paragraph of this Agreement and “Part” means a captioned part of this Agreement, (b) any word in this Agreement
is deemed to include the masculine, feminine, neuter, singular or plural form thereof as the context so required, (c) the captions and
headings used in this Agreement are for convenience only and do not constitute substantive matter and are not to be construed as interpreting
the contents of this Agreement, and (d) the word “including” is not limiting (whether or not non-limiting language
such as “without limitation” or “but not limited to” or other words of similar import are used with reference
thereto).

 

    6

     

    

 

	17.	Entire Agreement. This Agreement, including all Schedules hereto, forms the entire agreement among
the parties and supersedes all prior agreements, proposals or communications relative to the subject matter of this Agreement. Amendments
to or waivers of this Agreement will be effective only if in writing and signed by authorized representatives of all parties. Unless otherwise
expressly stated, if there is any necessary conflict between any of the terms of this Agreement and Schedules to this Agreement, this
Agreement will take precedence.

 

	18.	Acceptance. This Agreement is executed effective as of the day and year first above written and
may be executed in counterparts, each of which will constitute an original and all of which taken together will constitute one and the
same instrument, and delivery of the counterparts may be effected by means of electronic transmission. The reproduction of signatures
by electronic transmission will be treated as binding as if originals

 

ProMIS Neurosciences Inc.

 

	Per:	/s/ Eugene Williams	 
	 	Eugene Williams, Chairman and CEO	 
	 	 	 
	 	/s/ Larry Alstiel	 
	 	Larry Altstiel, Consultant	 

 

    7

     

    

 

SCHEDULE A

 

SERVICES

 

A1.          Services (Scope of Work).

 

The consultant, reporting to the
Executive Chairman or CEO, will perform the role of Chief Medical Officer. This work may include, but is not limited to:

- Overseeing the design and execution
of clinical trials

- Interacting with regulatory
authorities

- Supporting ProMIS efforts with
investors and potential partners

- Representing ProMIS in public
fora such as medical and other conferences

- Contributing to company strategy
formulation as a member of senior management

 

A2.          Location. The parties expect that
Consultant will generally perform the Services from his residence in Connecticut, or on occasion at the Company’s offices at CIC.
However, the Company may require that the Consultant travel from time to time (such travel to be reimbursed in accordance with the provisions
of this Agreement).

 

TERM

 

A3.          Termination at End of Term. The Agreement
will automatically terminate at the end of the Term without any requirement for notice or payment in lieu of notice by either party.

 

A4.          Termination During the Term. This Agreement
may be terminated at any time during the Term as follows:

 

(a)              
by the Consultant for any reason at any time upon thirty (30) days’ written notice to the Company, which the Company may
abridge or waive in its sole discretion;

 

(b)              
by the Consultant immediately upon notice if the Company has materially breached this Agreement and such breach remains uncured
after fifteen (15) days’ written notice from the Consultant to the Company describing the reasonable particulars of such breach;

 

(c)              
by the Company immediately upon written notice if the Consultant has materially breached this Agreement and such breach remains
uncured after fifteen (15) days’ written notice from the Company to the Consultant describing the reasonable particulars of such
breach;

 

(d)              
by the Company in circumstances where §A4(c) does not apply, for any reason at any time upon thirty (30) days’ written
notice to the Consultant, or in the Company’s sole discretion, payment in lieu of such notice;

 

(e)              
automatically upon the death or permanent disability of the Consultant; or

 

(f)               
upon the written, mutual agreement of both parties.

 

     

     

    

 

A5.          Taxes. From time to time, the Consultant
will advise the Company of the Consultant’s applicable sales or service tax registration numbers and will be responsible for collecting
from the Company and remitting all applicable excise, sales, goods and services, and use taxes imposed by any federal, state, provincial,
municipal or other governmental authority (each an “Applicable Tax”) on the Services. The Company will pay all such
Applicable Taxes to the Consultant. The Consultant will be responsible for any error or omission of Applicable Taxes and will promptly
indemnify the Company for any liability the Company incurs as a result of such error or omission by the Consultant.EX-4.9

 Exhibit 4.9 

SECOND SUPPLEMENTAL INDENTURE 
 This Second
Supplemental Indenture (this “Supplemental Indenture”), dated as of June 22, 2022 among the parties identified under the caption “Guaranteeing Subsidiaries” on the signature page hereto (each
individually, a “Guaranteeing Subsidiary” and together, the “Guaranteeing Subsidiaries”), Targa Resources Corp., a Delaware corporation (the “Issuer”), the other Subsidiary
Guarantors (as defined in the Indenture referred to herein) and U.S. Bank Trust Company, National Association, as trustee under the Indenture referred to below (the “Trustee”). 

W I T N E S S E T H 
 WHEREAS, the Issuer has
heretofore executed and delivered to the Trustee an indenture (the “Base Indenture”), dated as of April 6, 2022, as supplemented by that certain First Supplemental Indenture, dated as of April 6, 2022
(the “First Supplemental Indenture” and, together with the Base Indenture, the “Indenture”), providing for the issuance of the Company’s 4.200% Senior Notes due 2033 (the “2033
Notes”) and the Company’s 4.950% Senior Notes due 2052 (the “2052 Notes” and, together with the 2033 Notes, the “Notes”); 

WHEREAS, Section 3.2 of the Indenture provides that under certain circumstances each Guaranteeing Subsidiary shall execute and deliver to the Trustee a
supplemental indenture pursuant to which each Guaranteeing Subsidiary shall unconditionally guarantee all of the Issuer’s obligations under the Notes and the Indenture on the terms and conditions set forth herein (the “Note
Guarantee”); and 
 WHEREAS, pursuant to Section 9.01 of the Indenture, the Trustee is authorized to execute and deliver this Supplemental
Indenture. 
 NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged,
each Guaranteeing Subsidiary and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows: 
  

	1.	 Capitalized Terms. Capitalized terms used herein without definition shall have the meanings assigned to
them in the Indenture. 

  

	2.	 Agreement to Guarantee. Each Guaranteeing Subsidiary hereby agrees to provide an unconditional Guarantee
on the terms and subject to the conditions set forth in the Indenture including but not limited to Article X thereof. 

  

	3.	 No Recourse Against Others. No past, present or future director, officer, employee, incorporator,
stockholder or agent of each Guaranteeing Subsidiary, as such, shall have any liability for any obligations of the Issuer or each Guaranteeing Subsidiary under the Notes, any Note Guarantees, the Indenture or this Supplemental Indenture or for any
claim based on, in respect of, or by reason of, such obligations or their creation. Each Holder of the Notes by accepting a Note waives and releases all such liability. The waiver and release are part of the consideration for issuance of the Notes.

	4.	 NEW YORK LAW TO GOVERN. THE LAW OF THE STATE OF NEW YORK SHALL GOVERN AND BE USED TO CONSTRUE THIS
SUPPLEMENTAL INDENTURE. 

  

	5.	 Counterparts. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy
shall be an original, but all of them together represent the same agreement. 

  

	6.	 Effect of Headings. The Section headings herein are for convenience only and shall not affect the
construction hereof. 

  

	7.	 The Trustee. The Trustee shall not be responsible in any manner whatsoever for or in respect of the
validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by each Guaranteeing Subsidiary and the Issuer. 

Signature pages follow. 

  
 2 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed and
attested, all as of the date first above written. 
  

			
	GUARANTEEING SUBSIDIARIES
	
	TARGA SOUTHTEX ENERGY OPERATING LLC
	TARGA SOUTHTEX ENERGY LP LLC
	TARGA SOUTHTEX ENERGY GP LLC
	TARGA SOUTHTEX PROCESSING LLC
	TARGA RICH GAS SERVICES GP LLC
	TARGA RICH GAS UTILITY GP LLC
	TARGA SOUTHTEX MIDSTREAM T/U GP LLC
	TARGA FRIO LASALLE GP LLC
	T2 EAGLE FORD GATHERING COMPANY LLC
	T2 LASALLE GATHERING COMPANY LLC
		
	By:	 	 /s/ Scott Rogan

	Name: Scott Rogan
	Title: Senior Vice President – Finance and Treasurer
	
	T2 GAS UTILITY LLC
	
	By: T2 Eagle Ford Gathering Company LLC, its sole member
		
	By:	 	 /s/ Scott Rogan

	Name: Scott Rogan
	Title: Senior Vice President – Finance and Treasurer
	
	T2 LASALLE GAS UTILITY LLC
	
	By: T2 LaSalle Gathering Company LLC, its sole member
		
	By:	 	 /s/ Scott Rogan

	Name: Scott Rogan
	Title: Senior Vice President – Finance and Treasurer

  
 Signature Page to
Supplemental Indenture 
 (April 6, 2022 Indenture) 

 
			
	TARGA RICH GAS SERVICES LP
	
	By: Targa Rich Gas Services GP LLC, its general partner
		
	By:	 	 /s/ Scott Rogan

	Name: Scott Rogan
	Title: Senior Vice President – Finance and Treasurer
	
	TARGA SOUTHTEX TRANSMISSION LP
	TARGA RICH GAS UTILITY LP
	
	By: Targa Rich Gas Utility GP LLC, its general partner
		
	By:	 	 /s/ Scott Rogan

	Name: Scott Rogan
	Title: Senior Vice President – Finance and Treasurer
	
	TARGA SOUTHTEX MIDSTREAM UTILITY LP
	
	By: Targa SouthTex Midstream T/U GP LLC, its general partner
		
	By:	 	 /s/ Scott Rogan

	Name: Scott Rogan
	Title: Senior Vice President – Finance and Treasurer

  
 Signature Page to
Supplemental Indenture 
 (April 6, 2022 Indenture) 

 
			
	TARGA SOUTHTEX MUSTANG TRANSMISSION LTD.
	TARGA SOUTHTEX CCNG GATHERING LTD.
	TARGA SOUTHTEX MIDSTREAM MARKETING COMPANY LTD.
	TARGA SOUTHTEX NGL PIPELINE LTD.
	TARGA SOUTHTEX GATHERING LTD.
	
	By: Targa SouthTex Energy GP LLC, its general partner
		
	By:	 	 /s/ Scott Rogan

	Name: Scott Rogan
	Title: Senior Vice President – Finance and Treasurer
	
	TARGA FRIO LASALLE PIPELINE LP
	
	By: Targa Frio LaSalle Pipeline GP LLC, its general partner
		
	By:	 	 /s/ Scott Rogan

	Name: Scott Rogan
	Title: Senior Vice President – Finance and Treasurer

  
 Signature Page to
Supplemental Indenture 
 (April 6, 2022 Indenture) 

 
			
	ISSUER
	
	TARGA RESOURCES CORP.
		
	By:	 	 /s/ Scott Rogan

	Name: Scott Rogan
	Title: Senior Vice President – Finance and Treasurer

  
 Signature Page to
Supplemental Indenture 
 (April 6, 2022 Indenture) 

 
			
	TRUSTEE
	
	U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee
		
	By:	 	 /s/ Alejandro Hoyos

		 	 Alejandro Hoyos
 Authorized
Signatory

  
 Signature Page to
Supplemental Indenture 
 (April 6, 2022 Indenture)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]